BridgeBio May See Quicker Market Entry For Muscular Dystrophy Drug

 
• By Joseph Haas

BridgeBio and US FDA agreed on a path to accelerated approval for BB-418, a Phase III oral candidate for a subset of limb-girdle MD patients. If successful, it would bring BridgeBio’s third product to market.

MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
BridgeBio hopes to earn accelerated approval for its drug for a subset of MD patients

More from Clinical Trials

More from R&D